Japan’s Pig-Kidney Plan Is a Road to Approval—not an Approval

The kidney in Japan’s newest transplant announcement does not yet belong to a patient. It belongs to a calendar. PorMedTec, a startup born from research at Meiji University, says it is preparing with Hokkaido University Hospital and Shonan Kamakura General Hospital for Japan’s first company-sponsored clinical trial using kidneys from genetically engineered pigs. The stated ambition is to start the trial in 2028, apply for conditional marketing approval in 2029 and pursue full approval in 2033.

It is an arresting schedule, made more vivid by a July 21 briefing in Kamakura where surgeon Kazunari Tanabe described training to retrieve the organ from a donor pig. Pig and human kidneys have closely comparable vascular architecture, he said, allowing much of the familiar procurement equipment and surgical logic to carry over. The apparent familiarity is the point at which caution must begin. Similar anatomy does not erase a species boundary; a workable operation is not the same as a durable therapy; and an application date is not an approval date.

PorMedTec’s June agreement is an agreement to prepare. Its own notice says the parties will consult the relevant authorities and then finalize a clinical-trial plan. No Japanese recipient has been enrolled. No domestic company trial has been authorized. No genetically engineered pig kidney has Japanese marketing approval. The 2028, 2029 and 2033 milestones are targets proposed by the developer—not commitments made by the Pharmaceuticals and Medical Devices Agency or the Ministry of Health, Labour and Welfare.

What has happened—and what has not

The wording “company-sponsored trial” also matters. In Japan, a formal clinical trial intended to support a marketing application is not simply an innovative operation chosen by a hospital. It requires a defined investigational product, controlled manufacturing and records, a protocol, safety reporting, independent review and data suitable for regulatory scrutiny. A surgeon can judge whether an artery can be joined. Regulators must judge whether one donor kidney is reproducibly the same kind of medical product as the next—and whether its benefits justify risks that extend beyond the operating theatre.

Why Japan is looking for another source of kidneys

Kidneys filter metabolic waste and excess water from blood, regulate electrolytes and acid balance, help control blood pressure, signal the production of red blood cells and support bone metabolism. When they fail permanently, dialysis can replace part of the filtration work, but not the full living physiology of the organ. Haemodialysis usually ties a patient to repeated treatment sessions; peritoneal dialysis moves more of the work home but brings its own daily burdens and infection risks. Both can sustain life. Neither is a biological cure.

At the end of 2024, the Japanese Society for Dialysis Therapy counted 337,414 people receiving chronic dialysis. The population is old: the mean age was 70.27, and the mean age of those beginning dialysis that year was 71.69. Japan Organ Transplant Network data listed 14,983 people registered for a kidney transplant on June 30, 2026. Its historical analysis says recipients who obtained a deceased-donor kidney in 2002–23 had waited, on average, about 14 years and nine months.

Those numbers describe different populations and must not be added together. Most people on dialysis are not automatically transplant candidates. Advanced age, cancer, severe cardiovascular disease, active infection, frailty, personal preference and other factors may make transplantation unsuitable. The 15-year figure is an average among people who ultimately received a kidney, not a prediction issued to every person on the waiting list. Yet the scale and duration reveal the structural problem: suitable human kidneys are scarce, and a patient can spend a substantial part of adult life waiting.

Living donation and deceased donation remain the standards. A pig kidney, if it works, could eventually become a bridge to a human organ, an alternative for patients unlikely to receive one, or a longer-term replacement. Which role makes clinical sense cannot be decided by supply alone. It depends on survival, organ durability, infection, quality of life, the toxicity of immunosuppressive drugs, and a fair comparison with modern dialysis and human transplantation.

A roadmap is not a regulatory decision

Date or stage	What it means	What it does not mean
2024	PorMedTec reported Japan’s first domestic births of cloned, genetically modified pigs made for xenotransplant research.	No organ was authorized for implantation in a living Japanese patient.
2026	The company and hospital partners announced preparation for a proposed trial; domestic donor production and quality systems continued.	The announcement is not permission to enroll or operate.
2028 target	A company goal for beginning the trial after the protocol, product and sites clear required reviews.	Not a guaranteed start date and not marketing approval.
2029 target	A hoped-for application for conditional approval using the available evidence.	An application can be delayed, rejected or answered with requests for more data.
Conditional, time-limited approval	If the product and route qualify, Japan can in some circumstances allow limited marketing while efficacy and further safety are verified after approval.	Not proof of final efficacy; not automatically nationwide, insured or unrestricted care.
2033 target	The company’s objective for converting the program to full approval after further evidence.	Not a promise by PMDA or MHLW and not a deadline binding the regulator.

Japan’s conditional and time-limited approval framework was created to address therapies for which conventional development can be unusually difficult. Official guidance describes an evidentiary threshold in which safety has been recognized and efficacy can be inferred, followed by post-marketing confirmation and a new application before the period expires. The same guidance warns developers not to treat conditional approval as the final goal.

Whether and how a pig kidney will fit that route is for Japanese authorities to determine. A transplanted organ, donor animal, cell line, preservation process, immune-suppression regimen and lifelong surveillance system do not map neatly onto an ordinary pill. The legal classification, evidence package and conditions will require consultation with PMDA and MHLW. Even a successful application would not settle hospital readiness, reimbursement, allocation rules or the number of patients who could realistically receive the procedure.

How an engineered pig becomes a potential donor

The Japanese program begins with cells, not with breeding an ordinary farm pig and choosing a kidney. PorMedTec imported engineered cells developed with eGenesis and uses somatic-cell nuclear transfer—the cloning method in which the nucleus of a designed donor cell is placed into a pig egg whose own nucleus has been removed. The reconstructed embryo can then develop into a pig carrying the intended modifications in its cells. The purpose is reproducibility: a defined cellular design must become healthy animals whose organs meet consistent specifications.

This is not the creation of a human–pig hybrid. The organ remains porcine. The added human genes make selected proteins that help regulate immune and clotting reactions; they do not turn the pig or its kidney into a human organ.

The eGenesis donor platform is commonly summarized as 69 genomic edits, but the biological logic is clearer in three groups. First, three pig genes responsible for carbohydrate antigens are disabled, reducing targets recognized by antibodies already present in human blood. Second, seven human genes are inserted to help regulate complement, inflammation, coagulation and cellular immune signalling. Third, multiple copies of porcine endogenous retrovirus sequences embedded in the pig genome are inactivated.

Every verb in that description needs discipline. The edits reduce known hazards; they do not erase rejection or make infection impossible. They address selected mechanisms; they do not guarantee that all copies are edited identically in every production animal or that an organ has developed normally. PorMedTec says it will compare gene expression and other quality measures with pigs used in the U.S. program. Equivalence is a manufacturing objective to be demonstrated, not a fact created by importing the original cells.

Why the immune system attacks so violently

A human kidney from another person is foreign enough to require tissue matching and lifelong immunosuppression. A pig kidney carries additional molecular flags. Humans naturally possess antibodies against common pig carbohydrate antigens. When those antibodies bind to vessels in an unmodified pig organ, they can activate complement, damage the lining of capillaries and trigger clotting so rapidly that the graft fails within minutes or hours: hyperacute rejection.

Removing the three major carbohydrate targets has changed the field because it can prevent that immediate catastrophe. But later barriers remain. Antibodies can recognize other antigens. T cells, macrophages and natural killer cells can attack. Human and pig clotting systems can communicate badly, causing thrombosis or bleeding. Inflammation can injure the microvasculature. A kidney that survives the first week may still be lost to acute cellular or antibody-mediated rejection months later, and chronic injury may emerge over years.

Recipients therefore still need powerful immunosuppression. Experimental regimens have often blocked the CD40–CD154 co-stimulation pathway, alongside other drugs. Such suppression can make a foreign organ tolerable, but it also weakens defences against bacteria, viruses and fungi and can create blood, metabolic or malignant complications. The central clinical question is not simply, “Does the kidney make urine?” It is, “Does the whole treatment package let the person live longer and better at an acceptable risk?”

Why the kidney is the leading test organ

The kidney is not easy; it is comparatively observable and partly recoverable. Clinicians can follow urine output, creatinine, filtration estimates, protein leakage, blood pressure, biopsy findings and imaging. If the organ fails or dangerous rejection develops, surgeons may be able to remove it and return the patient to dialysis. A failing transplanted heart has no equivalent temporary fallback.

That rescue route lowers one category of risk, not all risk. A patient can still suffer major surgery, bleeding, clots, wound complications, sensitization that complicates a later human transplant, infection or toxicity from immunosuppression. Removal does not rewind the body to the day before transplantation. Early trials must therefore define when to biopsy, when to intensify treatment, when to explant and how to preserve eligibility for a later human kidney.

A 120-year history of hope, failure and redesign

Xenotransplantation—the transfer of living cells, tissues or organs between species—predates dialysis and modern immune biology. In 1906, French surgeon Mathieu Jaboulay attached pig and goat kidneys to human patients. The grafts did not function for long. Surgeons could connect vessels, but science had not yet explained blood-group incompatibility, antibody rejection or immunosuppression.

In 1963 and 1964, Keith Reemtsma’s team transplanted chimpanzee kidneys into 13 people. Most grafts failed within weeks, but one recipient lived for close to nine months and returned to work before dying suddenly. The experiment proved that another species’ kidney could support human life for more than a moment; it also exposed the enormous immunological, infectious and ethical cost of using nonhuman primates.

The field’s centre then moved toward pigs. Pigs mature quickly, can be bred in controlled herds, have organs of a practical size and avoid many of the welfare and pathogen concerns associated with primates. Molecular tools supplied the missing redesign. In the early 2000s, cloned pigs were produced without the gene for the major alpha-Gal antigen. In 2017, researchers reported viable pigs whose many endogenous retrovirus copies had been disabled with CRISPR. By the 2020s, multigene donors combined antigen removal, human protective proteins and virus-sequence inactivation.

What the living recipients have taught—and what they cannot

The recent U.S. cases changed xenotransplantation from an idea tested in primates and deceased human bodies into a question lived by patients. In March 2024, Massachusetts General Hospital transplanted an eGenesis kidney into Richard Slayman. He left the hospital and died nearly two months later; the hospital said there was no indication that the transplant caused his death. In April, NYU Langone transplanted a pig kidney into Lisa Pisano, who also depended on a heart pump. Poor kidney blood flow associated with the cardiac device led the team to remove the graft after about 47 days; she later died.

Towana Looney received an NYU pig kidney in November 2024 and lived with it for 130 days before rejection and declining function led to removal in April 2025. Tim Andrews received an eGenesis kidney at Massachusetts General in January 2025; after 271 days, declining function led to explantation and a return to dialysis. He subsequently received a human kidney in January 2026. Bill Stewart received another eGenesis kidney at Massachusetts General in June 2025; the latest public patient information reviewed for this article described him as living without dialysis.

Lesson supported by the cases	Question still open
A gene-edited pig kidney can perfuse, make urine and free some recipients from dialysis for months.	Can it function safely for years, and in how many patients?
An organ can sometimes be removed and dialysis resumed after loss of function.	What irreversible harm, sensitization or infection risk remains after explantation?
Teams have identified and treated episodes of rejection and infection.	Which immune regimen offers the best balance of graft protection and host defence?
A recipient can later receive a human kidney, as Andrews did.	Will xenotransplantation preserve that option reliably across a larger population?

These are not interchangeable cases. They used different donor designs, surgical additions, immune regimens and patient circumstances; several occurred under compassionate or expanded-access pathways, not randomized controlled trials. A handful of brave recipients can establish feasibility and reveal failure modes. They cannot provide a stable survival rate, prove superiority to dialysis or resolve rare infectious hazards. That is why U.S. regulators moved the field toward controlled trials—and why Japan cannot substitute American headlines for Japanese evidence.

The infection question belongs to society, not only the recipient

Ordinary transplantation carries infection risk because recipients are immunosuppressed and donor organs can transmit pathogens. Xenotransplantation adds a second reservoir: a species with microorganisms humans may not routinely test for, including organisms not yet recognized. Inactivating known endogenous retrovirus sequences addresses one theoretical pathway. It does not make a pig “virus-free,” and no list can rule out an unknown agent.

Japan’s revised 2025 guidance therefore treats infection control as a chain. Donor animals should come from designated-pathogen-free, biosecure facilities with controlled feed, water, personnel and records. Cells, pigs and organs need traceability and repeated screening. Procurement must prevent contamination. Recipients and close contacts need clear instructions for reporting unexplained illness. Stored blood and tissue samples must permit investigators to look backward if a new signal appears.

The guidance anticipates long-term—potentially lifelong—health surveillance. Samples and medical records should be retained for at least 30 years. While knowledge remains incomplete, recipients may be unable to donate blood, organs, tissues, milk or reproductive cells and may be asked to update contact information and cooperate with investigation or autopsy. These are not footnotes to consent. A person may accept surgical risk for personal benefit; accepting duties intended to protect family members and the public is a broader bargain.

What a Japanese trial must be built to answer

The first task is product identity. Developers must show that the intended edits are present, stable and expressed; that cloning has not introduced damaging abnormalities; that kidneys develop normally; and that production animals remain free of specified pathogens. Facilities must demonstrate biosecurity, animal traceability, release criteria, transport and procurement procedures. If manufacture expands, consistency must survive the expansion.

The second task is a clinically honest protocol. Who should enter first: older patients with limited access to a human donor, highly sensitized patients, or another carefully defined group? How long must they have been on dialysis? What cardiovascular reserve is necessary? Which infections or cancers exclude enrollment? U.S. trial criteria can inform the discussion, but they are not Japan’s criteria and should not be copied without local review.

Endpoints must extend beyond technical success. Early kidney function, dialysis independence and 24-week survival are useful, but so are hospitalization, infection, rejection, drug toxicity, pain, ability to work, mental health, caregiver burden and future eligibility for a human transplant. A protocol needs independent stopping rules and a rescue plan. It must also say what happens if a participant wishes to withdraw from research but public-health monitoring remains important.

The third task is comparison. A patient offered an experimental pig kidney is not choosing between “organ” and “nothing.” The alternatives may include improved dialysis, continued waiting, a living donor, a deceased donor or conservative care. Consent must present those paths without exaggerating a pig organ as a cure or minimizing the burdens of dialysis to make enrollment seem inevitable.

The animal, the patient and the public

Ethics begins before the operating room. Gene-edited, cloned pigs would be purpose-bred in high-barrier facilities, their lives medically controlled and ended for organ recovery. The possibility of saving human lives is morally weighty, but it does not cancel duties of humane housing, veterinary care, minimization of animal numbers and suffering, transparent oversight and serious examination of alternatives. Pigs are socially and cognitively complex animals, not interchangeable production components.

Justice continues after proof of concept. A technically successful therapy can remain inaccessible if production is expensive, only a few urban centres can provide it or lifelong drugs and surveillance are not covered. Allocation rules will need to decide whether pig kidneys supplement the human wait list, create a separate pathway or serve as bridges. Trial recruitment must avoid exploiting desperation and should include people who understand that the first participant may help future patients without receiving lasting benefit.

Culture and religion require conversation rather than assumptions. Some patients may object to a pig-derived organ; others may accept it under teachings that prioritize preserving life. The proper response is individualized, informed consent and access to trusted advisers—not declaring a single view for an entire faith or community.

What approval would mean—and what it would not

If Japan eventually grants conditional approval, the decision would mean that authorities found a defined use, manufacturing system and evidence package sufficient for limited, monitored access under stated conditions. It would not mean the kidney is risk-free, permanent or superior for every patient. It would not eliminate post-market evidence requirements. It would not by itself set reimbursement, expand every hospital’s capability or replace human organ donation.

Full approval would be stronger but not final in the everyday sense. Long-latency infections, chronic rejection and rare harms may only emerge with larger numbers and longer observation. Manufacturing changes would need control. Clinical guidelines would evolve. Recipients could remain connected to surveillance for decades.

For now, the Japanese project’s importance lies precisely in the work it has not finished. It joins domestic cloning, pathogen-controlled animal production, two transplant centres and a U.S.-developed genetic platform into a possible clinical pathway. It gives regulators and ethics committees something concrete to interrogate. And it offers people living through dialysis a reason for measured hope.

The most honest image is not a finish line in 2033. It is a series of gates: a healthy donor herd, a reproducible organ, an authorized protocol, a fully informed first participant, months of functioning, years of follow-up, public-health vigilance and evidence strong enough to survive independent review. Japan has drawn that road. It has not yet arrived.

Primary sources and evidence notes

This article distinguishes announcements and company targets from regulatory decisions. Japanese dialysis and waiting-list figures describe different populations. Patient outcomes are reported only to the latest public status found by July 21, 2026; the small, heterogeneous case series cannot establish comparative safety or efficacy.

• Jiji Press via nippon.com: July 21, 2026 briefing and PorMedTec’s stated 2028, 2029 and 2033 targets
• PorMedTec: basic agreement, authority consultations and proposed Japanese trial
• Meiji University: February 2024 birth of Japan’s first cloned, genetically modified donor pigs
• AMED: PorMedTec program evaluation, designated-pathogen-free production and development work
• Japan Organ Transplant Network: current kidney-waiting-list data
• Japan Organ Transplant Network: historical waiting-time explanation
• Japanese Society for Dialysis Therapy: 2024 annual dialysis overview
• Ministry of Health, Labour and Welfare: 2025 xenotransplant infection-control guidance
• Ministry of Health, Labour and Welfare: conditional and time-limited approval guidance
• eGenesis: donor design, U.S. investigational-trial clearance and expanded-access updates
• Nature: preclinical testing and design of the 69-edit donor platform
• Science / PMC: CRISPR inactivation of porcine endogenous retroviruses in pigs
• History review: early human kidney xenotransplantation and Reemtsma’s chimpanzee series
• NYU Langone: Towana Looney’s transplant and explantation
• National Kidney Foundation: later outcomes for U.S. pig-kidney recipients